항정신병제 시장 규모, 점유율, 성장 분석 : 치료 클래스별, 질환별, 약제별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Antipsychotic Drugs Market Size, Share, and Growth Analysis, By Therapeutic Class (First Generation, Second Generation), By Disease (Schizophrenia, Bipolar Disorder), By Drug, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1670215
리서치사:SkyQuest Technology Consulting Pvt. Ltd.
발행일:2025년 02월
페이지 정보:영문 197 Pages
라이선스 & 가격 (부가세 별도)
한글목차
항정신병제 시장 규모는 2023년 172억 7,000만 달러로 평가되며, 2024년 182억 7,000만 달러에서 2032년 286억 9,000만 달러로 성장하여 예측 기간(2025-2032년) 동안 5.8%의 CAGR로 성장할 것으로 예상됩니다.
세계 항정신병제 시장은 정신건강 문제에 대한 인식이 높아지고 조기 진단 및 치료를 촉진하기 위한 정부와 의료기관의 협력적 노력에 힘입어 강력한 성장세를 보이고 있습니다. 조현병, 양극성 장애와 같은 정신질환의 증가는 1세대 및 2세대 항정신병제의 수요를 견인하고 있습니다. 지속형 주사제(LAI)와 약리유전체학을 통한 맞춤형 치료의 혁신은 환자의 순응도와 치료 결과를 개선하고 있습니다. 또한, 실시간 인사이트를 제공하는 디지털 치료제의 부상과 함께 비정형 항정신병제로의 전환을 경험하고 있습니다. 존슨앤드존슨의 150억 달러 규모의 Intra-Cellular Therapies 인수와 같은 최근 인수 및 FDA 승인은 정신과 치료의 발전과 보다 안전하고 효과적인 치료법에 대한 수요 증가에 대응하기 위한 전략적 투자의 하이라이트입니다.
목차
소개
조사 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장 가정과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porters 분석
주요 시장 인사이트
핵심성공요인
경쟁 정도
주요 투자 기회
시장 생태계
시장 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
사례 연구
규제 상황
특허 분석
항정신병제 시장 규모 : 치료 클래스별 & CAGR(2025-2032년)
시장 개요
제1세대
제2세대
제3세대
항정신병제 시장 규모 : 질환별 & CAGR(2025-2032년)
시장 개요
정신분열증
양극성 장애
단극성 우울증
치매
기타 질환
항정신병제 시장 규모 : 약제별 & CAGR(2025-2032년)
시장 개요
Risperidone
Quetiapine
Olanzapine
Aripiprazole
Brexpiprazole
Paliperidone Palmitate
기타
항정신병제 시장 규모 : 유통 채널별 & CAGR(2025-2032년)
시장 개요
병원 약국
드럭스토어와 약국
온라인 약국
항정신병제 시장 규모 : 지역별 & CAGR(2025-2032년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5개사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채용한 전략
최근의 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업 개요
기업 상세
제품 포트폴리오 분석
기업 부문별 점유율 분석
매출 전년비 비교(2022-2024년)
주요 기업 개요
Johnson & Johnson(USA)
Otsuka Pharmaceutical Co., Ltd.(Japan)
Pfizer Inc.(USA)
Teva Pharmaceutical Industries Ltd.(Israel)
Eli Lilly and Company(USA)
AstraZeneca plc(UK)
GlaxoSmithKline plc(UK)
AbbVie Inc.(USA)
Bristol-Myers Squibb(USA)
H. Lundbeck A/S(Denmark)
Sumitomo Pharma Co., Ltd.(Japan)
Alkermes plc(Ireland)
Dr. Reddy's Laboratories(India)
Amgen Inc.(USA)
Sanofi S.A.(France)
Merck & Co., Inc.(USA)
Novartis International AG(Switzerland)
Roche Holding AG(Switzerland)
Takeda Pharmaceutical Company Limited(Japan)
Sun Pharmaceutical Industries Ltd.(India)
결론과 제안
ksm
영문 목차
영문목차
Antipsychotic Drugs Market size was valued at USD 17.27 billion in 2023 and is poised to grow from USD 18.27 billion in 2024 to USD 28.69 billion by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).
The global antipsychotic drugs market is witnessing robust growth, fueled by increased awareness of mental health issues and concerted efforts from governments and health organizations to promote early diagnosis and treatment. The rise in mental health disorders, such as schizophrenia and bipolar disorder, is driving demand for both first- and second-generation antipsychotic medications. Innovations in long-acting injectables (LAIs) and tailored therapies through pharmacogenomics are enhancing patient adherence and treatment outcomes. The market is also experiencing a shift towards atypical antipsychotics, coupled with the rise of digital therapeutics that provide real-time insights. Recent acquisitions and FDA approvals, such as Johnson & Johnson's $15 billion acquisition of Intra-Cellular Therapies, highlight strategic investments aimed at advancing psychiatric care and accommodating the growing demand for safer, effective treatments.
Top-down and bottom-up approaches were used to estimate and validate the size of the Antipsychotic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Antipsychotic Drugs Market Segments Analysis
Global Antipsychotic Drugs Market is segmented by Therapeutic Class, Disease, Drug, Distribution Channel and region. Based on Therapeutic Class, the market is segmented into First Generation, Second Generation and Third Generation. Based on Disease, the market is segmented into Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia and Other Diseases. Based on Drug, the market is segmented into Risperidone, Quetiapine, Olanzapine, Aripiprazole, Brexpiprazole, Paliperidone Palmitate and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Antipsychotic Drugs Market
A significant factor fueling the growth of the global antipsychotic drugs market is the escalating incidence of mental health disorders, such as schizophrenia and bipolar disorder. As awareness of these conditions rises, there is a growing demand for innovative treatment options as well as improved access to psychiatric care across the globe. This heightened understanding of mental health issues not only drives the development of new therapies but also emphasizes the necessity for comprehensive support systems for individuals affected by these disorders. Consequently, this trend is propelling the expansion of the antipsychotic drug market worldwide.
Restraints in the Antipsychotic Drugs Market
The global antipsychotic drugs market faces notable restraints, primarily due to regulatory challenges and protracted approval processes. These stringent regulations and extended clinical trial requirements hinder the timely introduction of new therapies, thereby impeding the speed at which groundbreaking medications can become available to patients. Such obstacles particularly affect market expansion in regions with rigid regulatory environments, further constraining the overall growth potential of the antipsychotic drug sector. Consequently, manufacturers and stakeholders must navigate these regulatory complexities, which can significantly delay the development and commercialization of innovative treatment options for mental health disorders.
Market Trends of the Antipsychotic Drugs Market
The antipsychotic drugs market is experiencing a notable trend towards the increasing demand for long-acting injectable antipsychotics, driven by the need for improved management of chronic psychiatric disorders such as schizophrenia. These innovative formulations allow for reduced dosing frequency, enhancing patient adherence and overall treatment effectiveness. Notably, pharmaceutical companies are investing in the development of new long-acting injectables that not only ensure sustained therapeutic efficacy but also prioritize patient convenience. This shift reflects a broader understanding of the complexities of mental health treatment, emphasizing the need for solutions that are both effective and user-friendly, positioning long-acting injectables as key players in the market's growth.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Patent Analysis
Global Antipsychotic Drugs Market Size by Therapeutic Class & CAGR (2025-2032)
Market Overview
First Generation
Second Generation
Third Generation
Global Antipsychotic Drugs Market Size by Disease & CAGR (2025-2032)
Market Overview
Schizophrenia
Bipolar Disorder
Unipolar Depression
Dementia
Other Diseases
Global Antipsychotic Drugs Market Size by Drug & CAGR (2025-2032)
Market Overview
Risperidone
Quetiapine
Olanzapine
Aripiprazole
Brexpiprazole
Paliperidone Palmitate
Others
Global Antipsychotic Drugs Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies
Global Antipsychotic Drugs Market Size & CAGR (2025-2032)
North America (Therapeutic Class, Disease, Drug, Distribution Channel)
US
Canada
Europe (Therapeutic Class, Disease, Drug, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Therapeutic Class, Disease, Drug, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Therapeutic Class, Disease, Drug, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Therapeutic Class, Disease, Drug, Distribution Channel)
